Novel Drugs for Intraperitoneal Therapy for Ovarian Cancer

摘要: Three phase III trials showing a superior outcome for intraperitoneal (IP) over intravenous (IV) drug delivery have encouraged the use of IP cisplatin (as in all three trials) and paclitaxel last trial) recently diagnosed optimally cytoreduced ovarian cancer. This chapter deals with other drugs that been studied clinically, should be considered subsequent utilizing route. Among cytotoxic agents, carboplatin topotecan several I II studies given encouraging results based on (1) strong rationale, (2) safety profile, (3) evidence activity favorable outcome. Gemcitabine docetaxel also merit further study alone or combination platinums. The route has utilized radioimmunoconjugates immune modulators such as interleukin-2 (IL-2) interferon (IFN), but their role was not confirmed limited experience. Finally, bevacizumab both preclinically clinically possible effect measures. Such treatment, by decreasing capillary flow into tumors may limit egress once it enters tumor compartment. Future need to consider addressing cytotoxics beyond paclitaxel, concomitant antiangiogenic drugs, consolidation after first-line treatment.